Susceptibility of anaerobic bacteria to FCE 22101 | Zendy

C. E. Nord | Zendy; A. Lindmark | Zendy; I Person | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Susceptibility of anaerobic bacteria to FCE 22101

Author(s) -

C. E. Nord,

A. Lindmark,

I Person

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.5.831

Subject(s) - imipenem , microbiology and biotechnology , cefoxitin , anaerobic bacteria , peptostreptococcus , clindamycin , piperacillin , clostridium perfringens , fusidic acid , anaerobic exercise , benzylpenicillin , antibiotics , chemistry , bacteroides fragilis , clostridium , medicine , bacteria , biology , penicillin , antibiotic resistance , staphylococcus aureus , physiology , genetics , pseudomonas aeruginosa

The activity of FCE 22101 against 675 strains of anaerobic bacteria was determined by an agar dilution method. Its activity was compared with those of benzylpenicillin, piperacillin, cefoxitin, imipenem, clindamycin, metronidazole, chloramphenicol, vancomycin, fusidic acid, and bacitracin. FCE 22101 and imipenem (MIC, less than or equal to 0.5 mg/liter) were the most active agents against the anaerobic strains tested, except against Clostridium difficile strains. On the basis of these results, FCE 22101 appears to be a promising antimicrobial agent for treatment of anaerobic infections, and further clinical investigations are indicated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research